Metabasis Therapeutics (MBRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Metabasis Therapeutics (MBRX)

MBRX 0.451

-4.8%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LJM who wrote (60)	4/7/2008 9:01:43 PM
From: Biotech Jim	of 66

I wonder if the C&E News article to be published will go into the comparative animal model efficacy or human drug exposure AUCs. Recall that based on glycosylated hemoglobin measures in an I believe 28 day study with CS917 failed to show efficacy, compared to the metformin comparator (which was a 0.5% reduction in HbAic, whereas 1-2% is viewed as a very good signal in longer term studies). An important question is will this mechanism work (well) in man. In that regard, are the metabolic characteristics of the compound sufficient to see efficacy in the ongoing study? What a powerful press release when one considers the combination of preclinical differentiative studies comparing MB07803 to CS917, the successful filing of an IND, the initiation and apparent sufficient completion of Ph1 studies to perform 28 day Ph2a studies and the completed enrollment of the Ph 2 proof of concept studies. Pretty quiet thread, huh? Disclosure: Watching MBRX and having an interest in diabetic mechanisms, as previously discussed some time back on Peter's Valuation thread. BJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next